AZD-6750

N/A

Report date: 2026/03/19 20:00:18
NME

Base Information

Drug NameAZD-6750
Drug Alias Namea CD8 Guided IL-2 AgentAZD6750AZD-6750
ClassificationBiologics
Mechanisms of ActionCluster of differentiation 8 modulators
TargetsCluster of differentiation 8
Therapy Area/IndicationsCarcinoma, Non-Small-Cell LungOvarian NeoplasmsStomach Neoplasms +[10] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesAustraliaSouth Korea +[4] 
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesAstrazeneca Plc
China Registration ClassN/A

Develop Information

Active CompaniesAstrazeneca Plc
Inactive CompaniesN/A
Active IndicationsCarcinoma, Non-Small-Cell LungOvarian NeoplasmsStomach Neoplasms +[10] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A